HEADER TRANSFERASE 30-APR-12 4ASE TITLE CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN TITLE 2 COMPLEX WITH TIVOZANIB (AV-951) COMPND MOL_ID: 1; COMPND 2 MOLECULE: VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: JUXTAMEMBRANE AND KINASE DOMAINS, RESIDUES 787-1171; COMPND 5 SYNONYM: VEGFR-2, FETAL LIVER KINASE 1, FLK-1, KINASE INSERT DOMAIN COMPND 6 RECEPTOR, KDR, PROTEIN-TYROSINE KINASE RECEPTOR FLK-1, CD309; COMPND 7 EC: 2.7.10.1; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PFASTBAC KEYWDS TRANSFERASE, ANGIOGENESIS, SIGNALING PROTEIN, PHOSPHORYLATION, KEYWDS 2 RECEPTOR, INHIBITOR EXPDTA X-RAY DIFFRACTION AUTHOR M.MCTIGUE,Y.DENG,K.RYAN,A.BROOUN,W.DIEHL,A.STEWART REVDAT 4 20-DEC-23 4ASE 1 REMARK REVDAT 3 08-MAY-19 4ASE 1 REMARK REVDAT 2 14-NOV-12 4ASE 1 JRNL REVDAT 1 26-SEP-12 4ASE 0 JRNL AUTH M.MCTIGUE,B.W.MURRAY,J.H.CHEN,Y.DENG,J.SOLOWIEJ,R.S.KANIA JRNL TITL MOLECULAR CONFORMATIONS, INTERACTIONS, AND PROPERTIES JRNL TITL 2 ASSOCIATED WITH DRUG EFFICIENCY AND CLINICAL PERFORMANCE JRNL TITL 3 AMONG VEGFR TK INHIBITORS. JRNL REF PROC.NATL.ACAD.SCI.USA V. 109 18281 2012 JRNL REFN ISSN 0027-8424 JRNL PMID 22988103 JRNL DOI 10.1073/PNAS.1207759109 REMARK 2 REMARK 2 RESOLUTION. 1.83 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.83 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 43.32 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1332184.640 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 98.7 REMARK 3 NUMBER OF REFLECTIONS : 33984 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.207 REMARK 3 FREE R VALUE : 0.231 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1022 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.007 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.83 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.94 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.60 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 5450 REMARK 3 BIN R VALUE (WORKING SET) : 0.3170 REMARK 3 BIN FREE R VALUE : 0.3120 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 3.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 167 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.024 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2455 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 32 REMARK 3 SOLVENT ATOMS : 249 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 26.20 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 42.30 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 12.32000 REMARK 3 B22 (A**2) : -9.74000 REMARK 3 B33 (A**2) : -2.58000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -3.28000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.22 REMARK 3 ESD FROM SIGMAA (A) : 0.29 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.26 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.27 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 0.800 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 19.80 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.590 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.37 REMARK 3 BSOL : 69.33 REMARK 3 REMARK 3 NCS MODEL : NONE REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : DNA-RNA_REP.PARAM REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : ION.PARAM REMARK 3 PARAMETER FILE 5 : UNL.PARAM REMARK 3 PARAMETER FILE 6 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : DNA-RNA.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : ION.TOP REMARK 3 TOPOLOGY FILE 5 : UNL.TOP REMARK 3 TOPOLOGY FILE 6 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4ASE COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 30-APR-12. REMARK 100 THE DEPOSITION ID IS D_1290052321. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 17-OCT-11 REMARK 200 TEMPERATURE (KELVIN) : 85 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : AUTOPROC REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 33988 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.830 REMARK 200 RESOLUTION RANGE LOW (A) : 43.200 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : 0.03000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.83 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.93 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.8 REMARK 200 DATA REDUNDANCY IN SHELL : 3.40 REMARK 200 R MERGE FOR SHELL (I) : 0.40000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNX REMARK 200 STARTING MODEL: PDB ENTRY 4ASD REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 53.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.60 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CRYSTALS WERE OBTAINED BY THE HANGING REMARK 280 DROP VAPOR DIFFUSION METHOD AT 13 DEGREES C BY THE USING REMARK 280 PRECIPITANT SOLUTIONS CONTAINING APPROXIMATELY: 0.2M SODIUM REMARK 280 CITRATE AND 14-21% (W/V) POLYETHYLENE GLYCOL 3350., PH 6.2, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 286K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 67.54750 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 28.14950 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 67.54750 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 28.14950 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, GLU 990 TO VAL REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 769 REMARK 465 GLY A 770 REMARK 465 GLY A 771 REMARK 465 HIS A 772 REMARK 465 HIS A 773 REMARK 465 HIS A 774 REMARK 465 HIS A 775 REMARK 465 HIS A 776 REMARK 465 HIS A 777 REMARK 465 GLY A 778 REMARK 465 LEU A 779 REMARK 465 GLU A 780 REMARK 465 VAL A 781 REMARK 465 LEU A 782 REMARK 465 PHE A 783 REMARK 465 GLN A 784 REMARK 465 GLY A 785 REMARK 465 PRO A 786 REMARK 465 ARG A 787 REMARK 465 THR A 788 REMARK 465 VAL A 789 REMARK 465 LYS A 790 REMARK 465 ARG A 791 REMARK 465 ALA A 792 REMARK 465 ASN A 793 REMARK 465 GLY A 794 REMARK 465 GLY A 795 REMARK 465 GLU A 796 REMARK 465 LEU A 797 REMARK 465 LYS A 798 REMARK 465 THR A 799 REMARK 465 GLY A 800 REMARK 465 TYR A 801 REMARK 465 LEU A 802 REMARK 465 SER A 803 REMARK 465 ILE A 804 REMARK 465 VAL A 805 REMARK 465 MET A 806 REMARK 465 VAL A 990 REMARK 465 ALA A 991 REMARK 465 PRO A 992 REMARK 465 GLU A 993 REMARK 465 ASP A 994 REMARK 465 LEU A 995 REMARK 465 GLN A 1170 REMARK 465 ASP A 1171 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 939 CA C O CB CG CD CE REMARK 470 LYS A 939 NZ REMARK 470 GLN A1169 CA C O CB CG CD OE1 REMARK 470 GLN A1169 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 HIS A 816 56.70 -118.49 REMARK 500 ARG A1027 -4.03 76.99 REMARK 500 ASP A1028 45.83 -149.68 REMARK 500 ASP A1112 -166.65 -112.33 REMARK 500 ALA A1168 52.93 -101.84 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE AV9 A 3169 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1VR2 RELATED DB: PDB REMARK 900 HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE REMARK 900 DOMAIN REMARK 900 RELATED ID: 1Y6A RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 2- ANILINO-5-ARYL- REMARK 900 OXAZOLE INHIBITOR REMARK 900 RELATED ID: 1Y6B RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 2- ANILINO-5-ARYL- REMARK 900 OXAZOLE INHIBITOR REMARK 900 RELATED ID: 1YWN RELATED DB: PDB REMARK 900 VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[2,3- D]PYRIMIDINE REMARK 900 RELATED ID: 2X1W RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VEGF-C IN COMPLEX WITH DOMAINS 2 AND 3 OF REMARK 900 VEGFR2 REMARK 900 RELATED ID: 2X1X RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VEGF-C IN COMPLEX WITH DOMAINS 2 AND 3 OF REMARK 900 VEGFR2 IN A TETRAGONAL CRYSTAL FORM REMARK 900 RELATED ID: 2XIR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF- REMARK 900 00337210 (N,2-DIMETHYL-6-(7-(2- MORPHOLINOETHOXY)QUINOLIN-4-YLOXY) REMARK 900 BENZOFURAN-3-CARBOXAMIDE) REMARK 900 RELATED ID: 4AG8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH REMARK 900 AXITINIB (AG-013736) (N-METHYL-2-(3-((E )-2-PYRIDIN-2-YL-VINYL)-1H- REMARK 900 INDAZOL-6-YLSULFANYL)- BENZAMIDE) REMARK 900 RELATED ID: 4AGC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN REMARK 900 COMPLEX WITH AXITINIB (AG-013736) (N- METHYL-2-(3-((E)-2-PYRIDIN-2- REMARK 900 YL-VINYL)-1H-INDAZOL -6-YLSULFANYL)-BENZAMIDE) REMARK 900 RELATED ID: 4AGD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN REMARK 900 COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5- REMARK 900 FLUORO-2-OXO-1H-INDOL-3 -YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3- REMARK 900 CARBOXAMIDE) REMARK 900 RELATED ID: 4ASD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN REMARK 900 COMPLEX WITH SORAFENIB (BAY 43-9006) REMARK 999 REMARK 999 SEQUENCE REMARK 999 IN ADDITION TO THE MUTATION E990V, RESIDUES 940-989 WERE ALSO REMARK 999 DELETED FROM THE CRYSTALLISED SEQUENCE. DBREF 4ASE A 787 1171 UNP P35968 VGFR2_HUMAN 787 1171 SEQADV 4ASE MET A 769 UNP P35968 EXPRESSION TAG SEQADV 4ASE GLY A 770 UNP P35968 EXPRESSION TAG SEQADV 4ASE GLY A 771 UNP P35968 EXPRESSION TAG SEQADV 4ASE HIS A 772 UNP P35968 EXPRESSION TAG SEQADV 4ASE HIS A 773 UNP P35968 EXPRESSION TAG SEQADV 4ASE HIS A 774 UNP P35968 EXPRESSION TAG SEQADV 4ASE HIS A 775 UNP P35968 EXPRESSION TAG SEQADV 4ASE HIS A 776 UNP P35968 EXPRESSION TAG SEQADV 4ASE HIS A 777 UNP P35968 EXPRESSION TAG SEQADV 4ASE GLY A 778 UNP P35968 EXPRESSION TAG SEQADV 4ASE LEU A 779 UNP P35968 EXPRESSION TAG SEQADV 4ASE GLU A 780 UNP P35968 EXPRESSION TAG SEQADV 4ASE VAL A 781 UNP P35968 EXPRESSION TAG SEQADV 4ASE LEU A 782 UNP P35968 EXPRESSION TAG SEQADV 4ASE PHE A 783 UNP P35968 EXPRESSION TAG SEQADV 4ASE GLN A 784 UNP P35968 EXPRESSION TAG SEQADV 4ASE GLY A 785 UNP P35968 EXPRESSION TAG SEQADV 4ASE PRO A 786 UNP P35968 EXPRESSION TAG SEQADV 4ASE VAL A 990 UNP P35968 GLU 990 ENGINEERED MUTATION SEQRES 1 A 353 MET GLY GLY HIS HIS HIS HIS HIS HIS GLY LEU GLU VAL SEQRES 2 A 353 LEU PHE GLN GLY PRO ARG THR VAL LYS ARG ALA ASN GLY SEQRES 3 A 353 GLY GLU LEU LYS THR GLY TYR LEU SER ILE VAL MET ASP SEQRES 4 A 353 PRO ASP GLU LEU PRO LEU ASP GLU HIS CYS GLU ARG LEU SEQRES 5 A 353 PRO TYR ASP ALA SER LYS TRP GLU PHE PRO ARG ASP ARG SEQRES 6 A 353 LEU LYS LEU GLY LYS PRO LEU GLY ARG GLY ALA PHE GLY SEQRES 7 A 353 GLN VAL ILE GLU ALA ASP ALA PHE GLY ILE ASP LYS THR SEQRES 8 A 353 ALA THR CYS ARG THR VAL ALA VAL LYS MET LEU LYS GLU SEQRES 9 A 353 GLY ALA THR HIS SER GLU HIS ARG ALA LEU MET SER GLU SEQRES 10 A 353 LEU LYS ILE LEU ILE HIS ILE GLY HIS HIS LEU ASN VAL SEQRES 11 A 353 VAL ASN LEU LEU GLY ALA CYS THR LYS PRO GLY GLY PRO SEQRES 12 A 353 LEU MET VAL ILE VAL GLU PHE CYS LYS PHE GLY ASN LEU SEQRES 13 A 353 SER THR TYR LEU ARG SER LYS ARG ASN GLU PHE VAL PRO SEQRES 14 A 353 TYR LYS VAL ALA PRO GLU ASP LEU TYR LYS ASP PHE LEU SEQRES 15 A 353 THR LEU GLU HIS LEU ILE CYS TYR SER PHE GLN VAL ALA SEQRES 16 A 353 LYS GLY MET GLU PHE LEU ALA SER ARG LYS CYS ILE HIS SEQRES 17 A 353 ARG ASP LEU ALA ALA ARG ASN ILE LEU LEU SER GLU LYS SEQRES 18 A 353 ASN VAL VAL LYS ILE CYS ASP PHE GLY LEU ALA ARG ASP SEQRES 19 A 353 ILE TYR LYS ASP PRO ASP TYR VAL ARG LYS GLY ASP ALA SEQRES 20 A 353 ARG LEU PRO LEU LYS TRP MET ALA PRO GLU THR ILE PHE SEQRES 21 A 353 ASP ARG VAL TYR THR ILE GLN SER ASP VAL TRP SER PHE SEQRES 22 A 353 GLY VAL LEU LEU TRP GLU ILE PHE SER LEU GLY ALA SER SEQRES 23 A 353 PRO TYR PRO GLY VAL LYS ILE ASP GLU GLU PHE CYS ARG SEQRES 24 A 353 ARG LEU LYS GLU GLY THR ARG MET ARG ALA PRO ASP TYR SEQRES 25 A 353 THR THR PRO GLU MET TYR GLN THR MET LEU ASP CYS TRP SEQRES 26 A 353 HIS GLY GLU PRO SER GLN ARG PRO THR PHE SER GLU LEU SEQRES 27 A 353 VAL GLU HIS LEU GLY ASN LEU LEU GLN ALA ASN ALA GLN SEQRES 28 A 353 GLN ASP HET AV9 A3169 32 HETNAM AV9 TIVOZANIB HETSYN AV9 1-{2-CHLORO-4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}- HETSYN 2 AV9 3-[(3E)-5-METHYLISOXAZOL-3(2H)-YLIDENE]UREA FORMUL 2 AV9 C22 H19 CL N4 O5 FORMUL 3 HOH *249(H2 O) HELIX 1 1 HIS A 816 LEU A 820 5 5 HELIX 2 2 ASP A 823 GLU A 828 1 6 HELIX 3 3 PRO A 830 ASP A 832 5 3 HELIX 4 4 THR A 875 GLY A 893 1 19 HELIX 5 5 LEU A 924 LYS A 931 1 8 HELIX 6 6 ARG A 932 GLU A 934 5 3 HELIX 7 7 THR A 1001 ARG A 1022 1 22 HELIX 8 8 ALA A 1030 ARG A 1032 5 3 HELIX 9 9 GLU A 1038 ASN A 1040 5 3 HELIX 10 10 PHE A 1047 ARG A 1051 5 5 HELIX 11 11 PRO A 1068 MET A 1072 5 5 HELIX 12 12 ALA A 1073 ARG A 1080 1 8 HELIX 13 13 THR A 1083 PHE A 1099 1 17 HELIX 14 14 ASP A 1112 GLY A 1122 1 11 HELIX 15 15 THR A 1132 TRP A 1143 1 12 HELIX 16 16 GLU A 1146 ARG A 1150 5 5 HELIX 17 17 THR A 1152 ASN A 1167 1 16 SHEET 1 AA 5 LEU A 834 ARG A 842 0 SHEET 2 AA 5 GLY A 846 PHE A 854 -1 O VAL A 848 N LEU A 840 SHEET 3 AA 5 CYS A 862 LEU A 870 -1 O ARG A 863 N ALA A 853 SHEET 4 AA 5 MET A 913 GLU A 917 -1 O VAL A 914 N LYS A 868 SHEET 5 AA 5 LEU A 901 CYS A 905 -1 N LEU A 902 O ILE A 915 SHEET 1 AB 3 GLY A 922 ASN A 923 0 SHEET 2 AB 3 ILE A1034 LEU A1036 -1 N LEU A1036 O GLY A 922 SHEET 3 AB 3 VAL A1042 ILE A1044 -1 O LYS A1043 N LEU A1035 SHEET 1 AC 2 VAL A1060 LYS A1062 0 SHEET 2 AC 2 ALA A1065 LEU A1067 -1 O ALA A1065 N LYS A1062 SITE 1 AC1 17 LEU A 840 VAL A 848 ALA A 866 LYS A 868 SITE 2 AC1 17 GLU A 885 LEU A 889 VAL A 899 VAL A 916 SITE 3 AC1 17 GLU A 917 CYS A 919 LYS A 920 LEU A1035 SITE 4 AC1 17 CYS A1045 ASP A1046 PHE A1047 HOH A2245 SITE 5 AC1 17 HOH A2246 CRYST1 135.095 56.299 51.991 90.00 96.33 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007402 0.000000 0.000821 0.00000 SCALE2 0.000000 0.017762 0.000000 0.00000 SCALE3 0.000000 0.000000 0.019352 0.00000